Schering AG was a research-centered German multinational pharmaceutical company headquartered in Wedding, Berlin, which operated as an independent company from 1851 to 2006. In 2006 it was bought by Bayer AG and merged to form the Bayer subsidiary Bayer Schering Pharma AG, which was renamed Bayer HealthCare Pharmaceuticals in 2011. Schering was listed on the Frankfurt Stock Exchange and had 26,000 employees as of 2004.

Repros Therapeutics Inc. ® was organized on August 20, 1987. We are a development stage biopharmaceutical company focused on the development of new drugs to treat hormonal and reproductive system disorders.

Manufactures pharmaceuticals and diagnostic substances

Janssen Pharmaceutica is a pharmaceutical company headquartered in Beerse, Belgium and owned by Johnson & Johnson. It was founded in 1953 by Paul Janssen. In 1961, Janssen Pharmaceutica was purchased by New Jersey-based American corporation Johnson & Johnson, and became part of Johnson & Johnson Pharmaceutical Research and Development (J&J PRD), now renamed to Janssen Research and Development (JRD), which conducts research and development activities related to a wide range of human medical disorders, including mental illness, neurological disorders, anaesthesia and analgesia, gastrointestinal disorders, fungal infection, HIV/AIDS, allergies and cancer. Janssen and Ortho-McNeil Pharmaceutical have been placed in the Ortho-McNeil-Janssen group within Johnson & Johnson Company.

Bayer Schering Pharma AG is a research-centered pharmaceutical company that was formed by the merger of Schering with Bayer on 29 December 2006. The company was originally founded in 1851 by Ernst Christian Friedrich Schering. The company employs more than 26,000 people in 140 subsidiaries all over the world. The company's headquarters are in Berlin-Wedding, Germany and the forerunner company Schering's annual gross revenue was nearly € 5 billion. They retain the largest German manufacturing facility which is located in Bergkamen. The company focuses on the business areas of gynaecology and andrology, oncology, and also special therapeutics, diagnostical devices, and nuclear medicine. Schering's best-known product is their line of combined oral contraceptive pills. Through Bayer Healthcare AG, Bayer Schering Pharma is a full member of the European Federation of Pharmaceutical Industries and Associations.

Eli Lilly engages in the discovery, development, manufacture, and sale of products in the pharmaceutical products business segment. The company manufactures and distributes products through owned or leased facilities in the United States, Puerto Rico, and 25 other countries. Its products are sold in approximately 135 countries. It also conducts research to find products to treat diseases in animals and to increase the efficiency of animal food production.

Allergan Pharmaceuticals International Ltd., a subsidiary of AbbVie, Inc., is a company headquartered in Ireland. The firm provides legal services.

Minerva Surgical is a commercial-stage medical technology company focused on developing, manufacturing, and commercializing minimally invasive solutions to meet the distinct uterine healthcare needs of women. The company has established a broad product line of commercially available, minimally invasive alternatives to hysterectomy, which are designed to address the most common causes of abnormal uterine bleeding (AUB) in most uterine anatomies. The Minerva Surgical solutions can be used in a variety of medical treatment settings and aim to address the drawbacks associated with alternative treatment methods and to preserve the uterus by avoiding unnecessary hysterectomies.

F. Hoffmann-La Roche Ltd. manufactures pharmaceutical products. It offers pharmaceutical drugs, pharmaceutical instruments, and diagnostics solutions. The company was founded by Fritz Hoffmann-La Roche on October 1, 1896 and is headquartered in Basel, Switzerland.

Cryo-Cell International, Inc. is cord blood bank, which engages in providing stem cell cryopreservation services and advancing regenerative medicine. It operates through the following segments: Cellular Processing and Cryogenic Storage, and Prepacyte CB. The Cellular Processing and Cryogenic Storage segment focuses on the collection and preservation of umbilical cord blood and tissue stem cells for family use. The Prepacyte CB segment refers to the processing technology used to process umbilical cord blood stem cells. The company was founded in 1989 and is headquartered in Oldsmar, FL.

Merck & Co., Inc. is a health care company, which engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. It operates through the following segments: Pharmaceutical, Animal Health, and Other. The Pharmaceutical segment includes human health pharmaceutical and vaccine products. The Animal Health segment discovers, develops, manufactures, and markets animal health products, such as pharmaceutical and vaccine products, for the prevention, treatment and control of disease in livestock, and companion animal species. The Other segment consists of sales for the non-reportable segments of healthcare services. The company was founded in 1891 and is headquartered in Kenilworth, NJ.

Igenomix SL is a biotechnology services company. It is engaged in providing non-invasive prenatal test, carrier genetic test, preimplantation diagnosis, sperm aneuploidy test, and endometrial receptivity array services. The company was founded by Carlos Simon Valles in 1996 and is headquartered in Paterna, Spain.

PregLem SA manufactures and markets pharmaceutical products specializing in gynecology and women's reproductive health. Its products include ESMYA, PGL2001, and PGL1001. The company was founded in June 2006 and is headquartered in Geneva, Switzerland.

sigma-tau is one of the most important Italian pharmaceutical groups, with a major presence also on the international stage. For more than half a century the company has been active in promoting the quality of life of man and his health. sigma-tau is present today in the most advanced research sectors, maintaining constant relations with scientific institutions with a world-wide reputation in the development of joint projects and in the implementation of original and innovative research programs. These results are the fruit of substantial, ongoing investment in research in the field of pharmaceutical innovation and stem not only from the efforts made to produce new products but also from the success of the company’s consolidated products. Bearing witness to sigma-tau’s achievements are not only the principles and values that inspire our efforts - innovation, dialogue and transparency, ethics, sustainability - but also the facts that have made sigma-tau a leading company in the research, manufacture and marketing of drugs.